What Are CD34 Positive Cells and Why Are They Important?

CD34 positive cells are cells that carry a specific protein, called CD34, on their surface. First identified in 1984, CD34 became the go-to marker for finding and isolating the stem cells responsible for generating all blood and immune cells in the body.¹ The protein’s importance stretches well beyond that original role, though. CD34 shows up on blood vessel lining cells, certain connective-tissue cells, muscle repair cells, and even cancer stem cells, making it one of the most broadly useful markers in modern medicine.²

The CD34 Protein Itself

CD34 is a heavily glycosylated transmembrane protein, which is a technical way of saying it sits on the cell surface coated in sugar molecules. It is encoded by a gene on chromosome 1.¹ At the molecular level, CD34 is involved in several jobs: it helps cells stick to one another (particularly lymphocytes to the blood vessel wall), it can boost cell division while blocking cells from maturing into specialized types, and it plays a role in shaping cell structure.² These functions make CD34 more than a passive label. It actively participates in how stem cells behave, including how they move through the body and settle into the tissues where they are needed.

CD34+ Cells as Blood-Forming Stem Cells

The most recognized role of CD34 positive cells is in hematopoiesis, the process by which the body continuously manufactures red blood cells, white blood cells, and platelets. In humans, most of the stem and progenitor cells responsible for this process carry CD34 on their surface. These cells live primarily in the bone marrow, nestled in specialized compartments called niches, where signals from surrounding cells help regulate whether they divide, stay dormant, or mature into a specific blood cell type.

Not all CD34+ cells are equal. Researchers subdivide them using additional surface markers. The most primitive population identified so far lacks many other markers and is characterized as CD34+CD38−CD90+CD45RA−.³ Using additional surface proteins like CD45RA, scientists have mapped out a hierarchy of progenitors, from the most versatile long-term repopulating cells down to committed progenitors that can only make one or two cell types.⁴ This hierarchy matters clinically because transplant outcomes depend not just on total CD34+ cell numbers but on the mix of primitive and committed cells within that population.

Where CD34+ Cells Come From

Three main sources supply CD34+ cells for clinical and research use: bone marrow, peripheral blood (after drug-induced mobilization), and umbilical cord blood. Each source has distinct properties. Bone marrow contains a higher proportion of CD34+ cells overall, while cord blood and mobilized peripheral blood contain more cells with active drug-efflux pump activity, a trait associated with the most primitive stem cells.⁵ Cord blood CD34+ cells also show higher proliferation rates in culture compared to adult sources, which partly explains why a relatively small cord blood unit can repopulate an entire blood system.⁶

To collect CD34+ cells from peripheral blood, doctors give the donor a drug that coaxes stem cells out of the bone marrow and into the bloodstream. A key player in this process is the interaction between a receptor called CXCR4, found on stem cells, and a signaling molecule called SDF-1α, released by support cells in the bone marrow. The drug plerixafor disrupts this interaction, effectively severing the anchor that holds stem cells in place and sending them into circulation.⁷ The mobilization is temporary and finely tuned; the body re-establishes the signaling balance once the drug clears.

Why CD34+ Cells Matter in Transplantation

Stem cell transplantation, used to treat blood cancers, bone marrow failure, and severe immune disorders, depends on infusing enough CD34+ cells to rebuild the patient’s blood and immune system. The CD34+ cell count in the graft is the single most commonly tracked predictor of whether and how quickly the transplant will “take.” A higher CD34+ dose is associated with faster recovery of neutrophils, the white blood cells that form the front line of infection defense.⁸ That said, the practical gain from pushing the dose higher and higher is modest once a baseline is met; one study found that each additional million CD34+ cells per kilogram shortened neutrophil recovery by only about four hours.

Mathematical modeling of transplant data has shown that while minimum cell-dose thresholds exist for safe engraftment, the optimal threshold varies between patients. People who engraft slowly in general stand to benefit more from a larger graft than those who would engraft quickly regardless.⁹ This kind of personalized dosing is an active area of interest, as transplant centers weigh the costs and logistics of collecting extra cells against the diminishing returns for patients who are already expected to recover well.

Counting CD34+ Cells

If the number of CD34+ cells in a transplant product determines clinical decisions, accurately counting them is critical. Flow cytometry is the standard method: cells are tagged with fluorescent antibodies that bind to CD34, then passed through a laser beam one at a time so that each cell’s markers can be read. In 1995, the International Society of Hematotherapy and Graft Engineering (ISHAGE) established a standardized protocol for this measurement to ensure labs around the world get comparable results.¹⁰ The single-platform version of this protocol, which counts cells and measures their CD34 status in one step rather than requiring separate instruments, is now considered the most reliable method available.¹¹

Getting this count right has real consequences. Overestimate the number of viable CD34+ cells in a graft, and a patient might receive a transplant that is too small to engraft safely. Underestimate it, and a donor might be asked to undergo an unnecessary extra collection procedure. The ISHAGE protocol reduced lab-to-lab variability and gave transplant teams a common language for what constitutes an adequate graft.

Isolating CD34+ Cells for Clinical Use

Many advanced therapies require not just a blood product that contains CD34+ cells, but a purified population of them. Immunomagnetic selection is the workhorse technology: tiny magnetic beads coated with anti-CD34 antibodies are mixed with the cell product, the CD34+ cells stick to the beads, and a magnet pulls them out while everything else washes away. The CliniMACS system, widely used in transplant centers, achieves CD34+ cell recoveries typically between about 50% and 80%, depending on processing details such as how aggressively platelets are removed beforehand.¹²

Newer automated versions of the system have been adapted to work with cryopreserved (frozen) stem cell products, achieving an average CD34 yield of around 53% with high purity and viability.¹³ For cord blood processing, tubing set design and sample age affect recovery significantly; one study found that a newer tubing set improved CD34+ recovery from about 45% to 56%.¹⁴ These numbers might sound low, but in practice the purity and viability of the recovered cells matter at least as much as the total yield, especially when those cells will undergo further manipulation such as gene editing.

CD34+ Cells in Gene Therapy

Some of the most exciting developments involving CD34+ cells have nothing to do with traditional transplantation. In gene therapy for inherited blood disorders, a patient’s own CD34+ cells are collected, genetically corrected outside the body, and infused back. This approach sidesteps the need for a matched donor entirely.

A landmark example is the use of CRISPR-Cas9 gene editing to treat sickle cell disease and transfusion-dependent beta-thalassemia. In an early report, CD34+ cells were collected from patients, edited to reactivate the gene for fetal hemoglobin, and reinfused after the patient’s existing bone marrow was cleared with chemotherapy. More than a year later, both patients had high levels of editing in their bone marrow, were producing fetal hemoglobin throughout their red blood cells, and no longer needed transfusions. The patient with sickle cell disease had no further pain crises.¹⁵ Lentiviral vector approaches, which deliver a corrective gene rather than editing the existing one, have also been developed and optimized for efficient transduction of CD34+ cells.¹⁶

Manufacturing these gene-modified CD34+ products at clinical scale requires meeting strict quality standards. In validation runs for a gene therapy targeting a metabolic storage disease, researchers achieved CD34+ cell viability above 94% and overall recovery of about 88% of the cells that were seeded for manufacturing, with final products meeting sterility and endotoxin release criteria.¹⁷ For cord blood-derived CD34+ cells being prepared as advanced therapy products, minimum quality thresholds have been defined: at least 500,000 viable CD34+ cells, at least 80% purity, and at least 70% viability, with studies confirming that banked cord blood stored for up to 16 years can still meet these standards.¹⁸

CD34 Beyond the Blood System

One of the more surprising findings of the last two decades is that CD34 is not exclusively a blood stem cell marker. It shows up on a variety of non-blood-forming cells throughout the body. In human skin, for example, immunostaining reveals abundant CD34+ cells in the dermis. Some are endothelial cells lining blood vessels, but a large population consists of spindle-shaped cells with extremely long, thin extensions called telocytes. These telocytes form networks around hair follicles, sweat glands, and small blood vessels, and are thought to participate in local tissue repair and communication between cells.¹⁹ Similar CD34+ telocytes in the scalp are strategically positioned near stem cell clusters, hinting at a role in skin regeneration and homeostasis.²⁰

CD34+ cells that are not derived from bone marrow also appear to play a role in vascular repair. Research has pointed to non-bone-marrow CD34+ cells as being essential for repairing the inner lining of injured arteries, a process called endothelial repair.²¹ This is a reminder that the CD34 protein is not a stem cell marker in the simple sense people sometimes assume. It is a surface molecule found on multiple cell types that share certain properties like the capacity for adhesion and migration, but that live in very different tissues and serve very different functions.

CD34 in Cancer Diagnosis and Prognosis

Because CD34 is associated with immature, rapidly dividing cells, it also appears on the surface of certain cancer cells, and its presence can carry diagnostic and prognostic weight. In acute myeloid leukemia (AML), the proportion of blast cells carrying CD34 has been used as a prognostic marker. In one study of 38 AML patients, those whose blasts were CD34 positive had a median survival of 150 days after intensive chemotherapy, while the median survival of CD34 negative patients had not been reached at 575 days. The relative risk of death was roughly five times greater in the CD34 positive group, independent of age.²²

More recent work has used advanced computational techniques to map the immunological profiles of CD34+ cells in patients with AML and myelodysplastic syndromes (MDS). Researchers identified distinct clusters of CD34+ cells in leukemia patients, including clusters enriched in leukemia stem cells and clusters highly positive for PD-L1, a molecule that helps cancer cells evade the immune system.²³ Separately, studies comparing MDS and AML patients to non-malignant cases have shown that the CD34+ blast compartment in these diseases is tilted toward anti-apoptotic (survival-promoting) activity and away from proliferation, a pattern that becomes more extreme as disease progresses from MDS to AML.²⁴

CD34 is also useful in diagnosing solid tumors. Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the digestive tract, frequently express both CD117 (Kit) and CD34 on their surface. This double-positive pattern is shared by specialized pacemaker-like cells in the gut wall called interstitial cells of Cajal, from which GISTs are thought to originate.²⁵ Pathologists routinely use CD34 staining alongside other markers to confirm GIST diagnoses and distinguish them from other abdominal tumors.²⁶

How Aging Affects CD34+ Cells

As people age, the blood-forming stem cell pool undergoes both quantitative and functional changes. Counterintuitively, the proportion of the most primitive CD34+CD38− stem cells in the bone marrow actually increases in people over 70. But the downstream progenitors shift: early B-lymphoid progenitors decline, while myeloid progenitors stay roughly the same. Functionally, the capacity of aged CD34+ cells to generate certain blood cell types drops, particularly myeloid cells in laboratory colony-forming assays.²⁷

At a broader level, aging stem cells tend to favor production of myeloid cells and platelets over lymphoid cells, contributing to the weakened immune responses seen in older adults. Certain clones within the stem cell pool may expand disproportionately with age, a phenomenon called clonal hematopoiesis. This clonal expansion has been linked not only to a higher risk of blood cancers but also, somewhat surprisingly, to cardiovascular disease.²⁸ The connection between aging blood stem cells and heart disease is still being worked out, but it underscores that CD34+ cell biology has implications well beyond transplant medicine.

Exercise and CD34+ Cell Mobilization

Your body does not keep all its CD34+ cells locked in the bone marrow. Circulating CD34+ cells are found in peripheral blood at low levels under normal conditions, and their numbers spike temporarily in response to physiological stress. Vigorous exercise is one of the most studied triggers. A bout of intense activity roughly doubles the number of CD34+ cells circulating in the blood, and this mobilization appears to be driven by adrenaline-like signaling through the beta-2 adrenergic receptor. In one experiment, blocking beta-2 receptors with the drug nadolol eliminated the exercise-induced rise in CD34+ cells, while blocking only beta-1 receptors with bisoprolol left the response largely intact.²⁹

Regular moderate exercise has more complicated effects. Reviews of the literature suggest that while acute intense exercise reliably bumps up circulating CD34+ cell counts in the short term, the effects of chronic training programs are inconsistent and likely depend on factors like exercise intensity, the person’s health status, and how the cells are measured. The subset of CD34+ cells that also carry the vascular growth factor receptor KDR, sometimes called angiogenic progenitor cells, appears to respond to both acute and habitual exercise, which may partially explain the vascular health benefits of staying active.³⁰

The Mouse Problem

Researchers often use mouse models to study stem cell biology, but CD34 behaves differently in mice and humans, which has caused real confusion over the years. In normal mouse blood formation, the stem cells with the greatest long-term repopulating power are actually CD34 negative or express very low levels of the protein, essentially the opposite of what happens in humans. To investigate whether this reflects a true species difference or just different gene regulation, scientists created transgenic mice carrying the entire human CD34 gene. In those mice, the human version of CD34 was expressed on most stem cell populations, including the ones that were negative or low for mouse CD34.³¹ This means the two species genuinely regulate the gene differently. It is a cautionary tale for anyone trying to translate mouse findings about CD34+ cells directly to human medicine: the marker does not mean the same thing in both organisms.